Back

Neuropathological and Functional Impact of Astrocyte-Derived Extracellular Vesicles in an Aged Model of Alzheimer's Disease

Quach, B. G.; Salehi, S.; Roufegarinejad, R.; Mante, M.; Florio, J. B.; Rissman, R.; Winston, C. N.

2026-02-16 neuroscience
10.64898/2026.02.13.705826 bioRxiv
Show abstract

Extracellular vesicles (EVs) are lipid-bound particles that transfer cargos between cells. While plasma neuronal-derived EVs (NEVs) from individuals with mild cognitive impairment (MCI) and Alzheimers disease (AD) have been reported to exhibit high pathogenic potential, this study examined the impact of astrocyte-derived EVs (AEVs) in an aged AD mouse model. Plasma AEVs were isolated from cognitively normal control (CNC), MCI, and AD individuals using GLAST-based immunocapture and AEV size, purity, and tetraspanin were validated by flow cytometry, nanoparticle tracking, and super-resolution microscopy. AEVs pooled by clinical cohort were injected into the hippocampus of 6-month-old female PSAPP mice. Behavioral, biochemical, and neuropathological outcomes were assessed 6 months later. Rotarod assessment revealed significant impairment in motor coordination (p<0.0001) in mice receiving MCI- and AD-AEVs compared with those receiving CNC-AEVs. Morris water maze (MWM) also demonstrated cognitive deficits in MCI- and AD-AEV injected mice; however, no overt changes were observed in the staining of amyloid plaque burden (6E10), and neuroinflammation (GFAP). Immunoblotting of 82E1 and 22C11 confirmed A{beta}/AAP levels remained similar across all injected mice, whereas increased cortical tau accumulation was observed in MCI- and AD-AEV injected mice. Cerebellar synaptic density (SY-38) remained unchanged. While plasma AEVs from healthy individuals may confer neuroprotective benefits, AEVs from cognitively impaired individuals promoted tau accumulation in an amyloidogenic mouse model. These findings suggest that AEVs may play a dual role in AD as both potential biomarkers and mechanistic drivers of neurodegeneration, highlighting their relevance as targets for future therapeutic strategies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Alzheimer's & Dementia
143 papers in training set
Top 0.2%
28.5%
2
Neurobiology of Disease
134 papers in training set
Top 0.5%
8.7%
3
Alzheimer's Research & Therapy
52 papers in training set
Top 0.4%
5.0%
4
Journal of Extracellular Vesicles
50 papers in training set
Top 0.1%
3.7%
5
Molecular Neurodegeneration
49 papers in training set
Top 0.2%
3.7%
6
International Journal of Molecular Sciences
453 papers in training set
Top 3%
3.0%
50% of probability mass above
7
Acta Neuropathologica Communications
81 papers in training set
Top 0.3%
3.0%
8
Aging Cell
144 papers in training set
Top 2%
2.1%
9
npj Parkinson's Disease
89 papers in training set
Top 0.7%
1.9%
10
Fluids and Barriers of the CNS
21 papers in training set
Top 0.1%
1.9%
11
Scientific Reports
3102 papers in training set
Top 55%
1.8%
12
ACS Chemical Neuroscience
60 papers in training set
Top 1%
1.7%
13
Molecular Neurobiology
50 papers in training set
Top 0.4%
1.5%
14
Journal of Neuroinflammation
50 papers in training set
Top 0.5%
1.4%
15
Neurobiology of Aging
95 papers in training set
Top 1%
1.4%
16
Brain
154 papers in training set
Top 3%
1.3%
17
Nature Communications
4913 papers in training set
Top 56%
1.3%
18
Journal of Neurochemistry
50 papers in training set
Top 0.3%
1.1%
19
Annals of Neurology
57 papers in training set
Top 2%
1.0%
20
Frontiers in Aging Neuroscience
67 papers in training set
Top 3%
0.9%
21
Journal of Alzheimer's Disease
43 papers in training set
Top 1.0%
0.9%
22
Journal of Proteome Research
215 papers in training set
Top 2%
0.9%
23
Brain Communications
147 papers in training set
Top 3%
0.8%
24
Frontiers in Neurology
91 papers in training set
Top 5%
0.8%
25
Molecular Psychiatry
242 papers in training set
Top 3%
0.8%
26
Alzheimer's & Dementia: Translational Research & Clinical Interventions
16 papers in training set
Top 0.7%
0.7%
27
Brain, Behavior, and Immunity
105 papers in training set
Top 3%
0.7%
28
Life Science Alliance
263 papers in training set
Top 2%
0.7%
29
Advanced Science
249 papers in training set
Top 21%
0.7%
30
Clinical Chemistry
22 papers in training set
Top 1.0%
0.7%